Nanoscale drug delivery systems for cancer therapy using paclitaxel— A review of challenges and latest progressions

Mustafa, Ghulam; Hassan, Dilawar; Ruiz-Pulido, Gustavo; Pourmadadi, Mehrab; Eshaghi, Mohammad Mahdi; Behzadmehr, Razieh; Tehrani, Fatemeh Karami; Rahdar, Abbas; Medina, Dora I.; Pandey, Sadanand

doi:10.1016/j.jddst.2023.104494

Cited by 13 publications

(3 citation statements)

References 353 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The ability to use nanoplatforms to disrupt resistance mechanisms is a potential treatment technique for cancer ( 111 ). A folate-formed solid lipid nanoparticle can do this differentially and sequentially by providing two coexemplified anticancer drugs, paclitaxel (PTX) and curcumin (CUR), so that CUR, which is capable of inhibiting P-gp, begins to be administered sooner than PTX ( 112 ). As a result, P-gp inhibition in MCF-7/ADR BreC-safe cells is ensured, allowing PTX accumulation within.…”

Section: Drug Resistance and Epithelial Mesenchyme Transitionmentioning

confidence: 99%

Lipid-based nanoparticles as drug delivery carriers for cancer therapy

Waheed,

Ali,

Tabassum

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

Cancer is a severe disease that results in death in all countries of the world. A nano-based drug delivery approach is the best alternative, directly targeting cancer tumor cells with improved drug cellular uptake. Different types of nanoparticle-based drug carriers are advanced for the treatment of cancer, and to increase the therapeutic effectiveness and safety of cancer therapy, many substances have been looked into as drug carriers. Lipid-based nanoparticles (LBNPs) have significantly attracted interest recently. These natural biomolecules that alternate to other polymers are frequently recycled in medicine due to their amphipathic properties. Lipid nanoparticles typically provide a variety of benefits, including biocompatibility and biodegradability. This review covers different classes of LBNPs, including their characterization and different synthesis technologies. This review discusses the most significant advancements in lipid nanoparticle technology and their use in medicine administration. Moreover, the review also emphasized the applications of lipid nanoparticles that are used in different cancer treatment types.

show abstract

Section: Drug Resistance and Epithelial Mesenchyme Transitionmentioning

confidence: 99%

Lipid-based nanoparticles as drug delivery carriers for cancer therapy

Waheed,

Ali,

Tabassum

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…However, the addition of Cremophor EL results in hypersensitivity, neurotoxicity, and altered pharmacokinetics of PTX. Currently, several strategies are in progress to develop a CrEL-free formulation of PTX, including biological approaches (oral administration), chemical approaches (prodrugs/analogs), and pharmaceutical approaches (use of co-solvents, emulsions, cyclodextrins, microspheres, and liposomes) [23,24]. PTX is widely used to treat breast cancer, one of the most common clinical cancers in the world, and the main cause of cancer-related death in women; however, its therapeutic efficacy is limited, due to the development of resistance.…”

Section: Introductionmentioning

confidence: 99%

Colloidal and Biological Characterization of Dual Drug-Loaded Smart Micellar Systems

Herman,

Rata,

Cadinoiu

et al. 2024

Polymers

View full text Add to dashboard Cite

Smart polymeric micelles (PMs) are of great interest in drug delivery owing to their low critical micellar concentration and sizes. In the present study, two different pH-sensitive poly(2-vinyl pyridine)-b-poly(ethylene oxide) (P2VP-b-PEO) copolymer samples were used for the encapsulation of paclitaxel (PTX), ursolic acid (UA), and dual loading of PTX and UA. Based on the molecular features of copolymers, spherical PMs with sizes of around 35 nm and 140 nm were obtained by dialysis for P2VP55-b-PEO284 and P2VP274-b-PEO1406 samples, respectively. The micellar sizes increased after loading of both drugs. Moreover, drug encapsulation and loading efficiencies varied from 53 to 94% and from 3.2 to 18.7% as a function of the copolymer/drug ratio, molar mass of copolymer sample, and drug type. By FT-IR spectroscopy, it was possible to demonstrate the drug loading and the presence of some interactions between the polymer matrix and loaded drugs. In vitro viability was studied on 4T1 mammary carcinoma mouse cells as a function of time and concentration of drug-loaded PMs. UA-PMs and free PMs alone were not effective in inhibiting the tumor cell growth whereas a viability of 40% was determined for cells treated with both PTX- and PTX/UA-loaded PMs. A synergic effect was noticed for PTX/UA-loaded PMs.

show abstract

“…However, this second generation treatment is still dose-limited by tolerability of the PTX side effects and has not definitively improved patient outcomes compared to Taxol. To overcome the serious side effects of PTX-containing therapeutics stemming from the PTX carriers as well as from off-target effects of PTX against healthy cells, new delivery systems for PTX and other cytotoxic drugs are being developed [12,13,[18][19][20][21][22][23][24].…”

Section: Introductionmentioning

confidence: 99%

Lipids with negative spontaneous curvature decrease the solubility of the cancer drug paclitaxel in liposomes

Steffes,

MacDonald,

Crowe

et al. 2023

Preprint

View full text Add to dashboard Cite

Paclitaxel (PTX) is a hydrophobic small-molecule cancer drug that loads into the membrane (tail) region of lipid carriers such as liposomes and micelles. The development of improved lipid-based carriers of PTX is an important objective to generate chemotherapeutics with fewer side effects. The lipids 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) and glyceryl monooleate (GMO) show propensity for fusion with other lipid membranes, which has led to their use in lipid vectors of nucleic acids. We hypothesized that DOPE and GMO could enhance PTX delivery to cells through a similar membrane fusion mechanism. As an important measure of drug carrier performance, we evaluated PTX solubility in cationic liposomes containing GMO or DOPE. Solubility was determined by time-dependent kinetic phase diagrams generated from direct observations of PTX crystal formation using differential-interference-contrast optical microscopy. Remarkably, PTX was much less soluble in these liposomes than in control cationic liposomes containing univalent cationic lipid 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) and 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC), which are not fusogenic. In particular, PTX was not substantially soluble in GMO-based cationic liposomes. The fusogenicity of DOPE and GMO is related to the negative spontaneous curvature of membranes containing these lipids, which drives formation of nonlamellar self-assembled phases (inverted hexagonal or gyroid cubic). We used synchrotron small-angle x-ray scattering to determine whether PTX solubility is governed by lipid membrane structure (condensed with DNA in pellet form) or by local intermolecular interactions. The results suggest that local intermolecular interactions are of greater importance and that the negative spontaneous curvature-inducing lipids DOPE and GMO are not suitable components of lipid carriers for PTX delivery regardless of carrier structure.

show abstract

Nanoscale drug delivery systems for cancer therapy using paclitaxel— A review of challenges and latest progressions

Cited by 13 publications

References 353 publications

Lipid-based nanoparticles as drug delivery carriers for cancer therapy

Lipid-based nanoparticles as drug delivery carriers for cancer therapy

Colloidal and Biological Characterization of Dual Drug-Loaded Smart Micellar Systems

Lipids with negative spontaneous curvature decrease the solubility of the cancer drug paclitaxel in liposomes

Contact Info

Product

Resources

About